MedKoo Cat#: 464119 | Name: Ansofaxine HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ansofaxine, also known as toludesvenlafaxine, is a triple reuptake inhibitor, targeting serotonin, dopamine and norepinephrine. Toludesvenlafaxine had high binding affinity on SERT, NET and DAT, and significantly inhibited the reuptake of serotonin (IC50 = 31.4 ± 0.4 nM), norepinephrine (IC50 = 586.7 ± 83.6 nM) and dopamine (IC50 = 733.2 ± 10.3 nM) in vitro. Toludesvenlafaxine demonstrated significant antidepressant-like effects in rat models at 8-16 mg/kg. In addition, toludesvenlafaxine significantly reduced serum corticosterone and significantly increased testosterone levels in rats.

Chemical Structure

Ansofaxine HCl
CAS#916918-84-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 464119

Name: Ansofaxine HCl

CAS#: 916918-84-8 (HCl)

Chemical Formula: C24H32ClNO3

Exact Mass: 0.0000

Molecular Weight: 417.97

Elemental Analysis: C, 68.97; H, 7.72; Cl, 8.48; N, 3.35; O, 11.48

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Ansofaxine HCl; Ansofaxine hydrochloride; Toludesvenlafaxine; LPM570065; LPM 570065; LPM-570065; LY03005; LY-03005; LY 03005;
IUPAC/Chemical Name
4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenyl 4-methylbenzoate hydrochloride
InChi Key
BVWFJKQJRNSYCR-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H31NO3.ClH/c1-18-7-9-20(10-8-18)23(26)28-21-13-11-19(12-14-21)22(17-25(2)3)24(27)15-5-4-6-16-24;/h7-14,22,27H,4-6,15-17H2,1-3H3;1H
SMILES Code
O=C(OC1=CC=C(C(C2(O)CCCCC2)CN(C)C)C=C1)C3=CC=C(C)C=C3.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM comments
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 417.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H. Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. Pharmacopsychiatry. 2022 Jul;55(4):193-202. doi: 10.1055/a-1714-9097. Epub 2022 Jan 19. PMID: 35045580; PMCID: PMC9259184. 2: Mi W, Yang F, Li H, Xu X, Li L, Tan Q, Wang G, Zhang K, Tian F, Luo J, Xia J, Yuan K, Lu L, Deng J, Tian J, Zhang H. Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):252-260. doi: 10.1093/ijnp/pyab074. PMID: 34747448; PMCID: PMC8929756. 3: Mi W, Di X, Wang Y, Li H, Xu X, Li L, Wang H, Wang G, Zhang K, Tian F, Luo J, Yang C, Zhou Y, Xie S, Zhong H, Wu B, Yang D, Chen Z, Li Y, Chen J, Lv S, Yi Q, Jiang Z, Tian J, Zhang H. A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Transl Psychiatry. 2023 May 10;13(1):163. doi: 10.1038/s41398-023-02435-0. PMID: 37164957; PMCID: PMC10171157. 4: Fasipe OJ. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019 Jan 9;6:95-110. doi: 10.1016/j.ibror.2019.01.001. PMID: 31211282; PMCID: PMC6562183. 5: Vasiliu O. Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder-A Narrative Review. Pharmaceuticals (Basel). 2023 Mar 8;16(3):411. doi: 10.3390/ph16030411. PMID: 36986510; PMCID: PMC10051807.